Occupier

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Renowned biotechnology exec & former Alnylam CEO John Maraganore has joined Evox Therapeutics

28 Feb 2022

Renowned biotechnology executive and former Alnylam CEO John Maraganore has joined Evox Therapeutics Ltd as an advisor. The company said – ‘We look forward to his counsel as we advance our exosome therapeutics programs in rare diseases.’ Read more

Enara Bio announces the appointment of T-cell therapy leader  Dr. Sophie Papa as Chief Medical Officer

01 Feb 2022

Enara Bio announces the appointment of T-cell therapy leader Dr. Sophie Papa as Chief Medical Officer Oxford, UK – 1st February 2022. Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific antigens, announces the appointment of Dr. Sophie Papa, FRCP, PhD as Chief Medical Officer. Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and... Read more

Exscientia & Sanofi Establish Collaboration to Develop AI-driven Pipeline of Medicines

07 Jan 2022

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines January 7, 2022 * Collaborative efforts aim to accelerate drug discovery and improve clinical success * Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection * Research will be focused on up to 15 novel small molecule... Read more

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

06 Jan 2022

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has been appointed Non-Executive Chair of Oxford Cancer Biomarkers Ltd. She will take a leading role in helping the company achieve its growth and funding goals at a pivotal stage of the business, building on the two recent commercial launches of cancer... Read more

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics

05 Jan 2022

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics Oxford, UK – 5th January 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, today announced that the first patient had been dosed in a first-in-human clinical investigation (ISRCTN17598292) evaluating its proprietary SonoTran® Platform. SonoTran is being evaluated in a phase... Read more

News